2021 Guidelines on the management of patients with diabetes. A position of Diabetes Poland

Current Topics in DiabetesOfficial Journal of the Diabetes Poland At lit p aborundae.Bore quibus.El moluptas ipsuntia dolo di volupture dis dolenti asperspisit aut iniscit autem autae siniento tem re dolorum aut molupta Tatquae consequi doluptatum doluptatem Itatem que ipsum harciet vendit volecersped molut ea vid etur, sitaqui dolum imus, tota debis distem sam quae eat porrum raeped quid Explique poresequae preresc iditasp ererovitis ma plitin prores eseria nis nam, ipiscil es dolupid minvento doles voluptas cus.Equam, cuptatia quis quo maio.Itate sedignatur apid et faccuptatqui voluptas ut essimi, aperis de lit es ut etur?Tur arum sime moditiae.Exp am, sit elestem.Upis molore ipsant et quam, nimpost, utem dentinim endandam, sed eost, te nul abo.Et as volupta tiamus. kod kreskowyThe 2023 Diabetes Poland guidelines -summary of the most important changes Every year since 2005, the Diabetes Poland (PTD) prepares and publishes clinical guidelines for the management of people with diabetes.The originator and initiator of the set of guidelines was, in 2004, Prof. Jacek Sieradzki, who was the chairman of PTD during that time.The first chairman of the PTD Recommendations Panel was Prof. Władysław Grzeszczak, who held this position betwen 2005 and 2011.In the following term (2011-2015) these duties were taken over by the next chairman of the PTD, Prof. Leszek Czupryniak.In 2015-2019 the coordinator of the Recommendations Panel became Prof. Dorota Zozulińska-Ziółkiewicz, the representative of the PTD Executive Board for Clinical Recommendations.These recommendations are the result of the work of a group of approximately 50 experts from various fields of clinical sciences.The recommendations address many key aspects of clinical care for people with diabetes.The individual chapters are prepared by subteams coordinated by the leaders.The work of Experts is intended to improve prevention, diagnosis and treatment of diabetes and its complications in Poland.Advances in diabetology, results of further clinical and experimental studies, data from epidemiological observations and diabetes registries are reflected in the PTD Recommendations.This results in some modifications and new content every year.It is considered good practice that, from the outset conducted in accordance with EBM principles, PTD Recommendations require only a slight evolution related to new knowledge from sound, evidence-based research with important implications for clinical practice.Many up-to-date scientific study reports on diabetes have been published in 2022.Publication of new ADA/EASD clinical recommendations on the management of people with type 2 diabetes and new ISPAD recommendations were two important events.A summary of the most important changes can be found below.. Summary of the most important changes in the 2023 PTD recommendations Level of evidence Description AClear evidence from well-conducted, generalizable randomized controlled trials that are adequately powered, including:• Evidence from a well-conducted multicentre trial • Evidence from a meta-analysis that incorporated quality ratings in the analysis Compelling nonexperimental evidence, i.e., "all or none" rule developed by the Centre for Evidence-Based Medicine at the University of Oxford Supportive evidence from well-conducted randomized controlled trials that are adequately powered, including: • Evidence from a well-conducted trial at one or more institutions • Evidence from a meta-analysis that incorporated quality ratings in the analysis B Supportive evidence from well-conducted cohort studies • Evidence from a well-conducted prospective cohort study or registry • Evidence from a meta-analysis of cohort studies Supportive evidence from well-conducted case-control study C Supportive evidence from poorly or incontrolled studies • Evidence from randomized clinical trials with one or more major or three or more minor methodological flaws that could invalidate the results • Evidence from observational studies with high potential for bias (such as case series with comparison with historical controls) • Evidence from case series or case reports Conflicting evidence with the weight of evidence supporting the recommendation E Expert consensus or clinical experience 2023 Guidelines on the management of patients with diabetes A position of Diabetes Poland Principles of diagnosing glucose tolerance disorders Key recommendations• Blood glucose tests for early detection of prediabetes/type 2 diabetes should be performed for people over 45 years of age, as well as for younger overweight or obese people if there is at least one additional risk factor of diabetes.[B]• Women not previously diagnosed with diabetes should undergo an oral glucose tolerance test between 24 th and 28 th week of pregnancy to diagnose gestational diabetes.[A]